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IntroductIon Clinical practice guidelines 
(CPG) are becoming one of the basic educational 
and informational tools for physicians. Scientific 
associations and other organizations, whether lo­
cal, national or inter national, develop such docu­
ments, expecting their members and other users 
of the guidelines to act according to their recom­
mendations. Compliance with CPG recommenda­
tions is sometimes used as an index of health care 
quality, and the number of CPG is increasing. It is 
not infrequent that CPG addressing the same clin­
ical situations are issued independently by differ­
ent organizations. For example, physicians inter­
ested in treatment of venous thromboembolism 
may take advantage of current documents issued 
by American College of Chest Physicians1, Amer­
ican College of Physicians/American Academy 
of Family Physicians2, American Society of Clin­
ical Oncology3, Institute for Clinical Systems Im­
provement4, International Union of Angiology 
in cooperation with other inter national scientif­
ic associations5, National Comprehensive Cancer 
Network6 and National Institute for Health and 
Clinical Excellence7. Recommendations includ­
ed in individual CPG are frequently similar, but 
sometimes differ. There are numerous reasons 
for which various scientific associations or orga­
nizations develop independent documents deal­
ing with similar clinical situations, starting from 
local conditions, like availability of drugs, com­
mon prevention methods, etc, through the needs 
of specific groups and organizations, to differenc­
es of opinions.
It is important for users, i.e. physicians, nurses, 
physiotherapists, patients and other inter ested 
parties, to have an opportunity to recognize and 
select CPG with the best odds of benefiting pa­
tients to whom CPG are applied. However, such 
choice is difficult, because it is not easy to assess 
which guidelines are “the best”. Many publica­
tions do not even allow the reader to be precise­
ly aware to whom they are directed to, what ev­
idence serve as the basis for recommendations 
or what was the association between the authors 
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Clinical practice guidelines constitute one of the most important sources of information and educa‑
tion for physicians. Therefore, establishing rules to develop and appraise such guidelines properly 
is of increasing importance. This task is served by the AGREE (Appraisal of Guidelines Research 
and Evaluation) instrument, a questionnaire, which, according to its authors, allows reproducible 
assessment of guideline quality. The aim of this paper is to allow readers familiarize themselves 
with such rules of guidelines appraisal. In order to achieve this purpose, we present the actual ap‑
plication of the AGREE instrument using as an example recently published document on postmeal 
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developers, physicians and health care provid­
ers attempting to independently assess the qual­
ity of guidelines before making decisions about 
implementing their recommendations, and 
by those involved in education within a given 
field of medicine.
The AGREE consists of 23 key items organized 
in 6 domains. Each domain pertains to a sep­
arate dimension of CPG quality. The first one, 
scope and purpose (3 items), is to assess the pre­
cision of the clinical questions. The second one 
pertains to stakeholder involvement (4 items) and 
assesses the extent to which the guideline repre­
sents the views of its intended users. The follow­
ing group of seven items (rigor of CPG develop­
ment) relates to the process used to gather and 
synthesize the evidence, the method to formu­
late the recommendations and to update them. 
The fourth domain (clarity and presentation – 
4 items) deals with the language and format. 
The following domain (applicability, 3 items) as­
sesses the organizational, behavioural and cost 
implications of guideline application. The last 
covered domain (2 items) is independence, de­
fining the extent of independence of recommen­
dations and acknowledgement of possible con­
flict of inter est from the guideline development 
group.
Answers to the questions concerning individual 
quality criteria are rated on a 4­point scale (from 
1 – “strongly disagree”, through 2 – “disagree”, 3 – 
“agree” to 4 – “strongly agree”). Although the as­
sessment results in individual domains could 
be found helpful while comparing quality of dif­
ferent guidelines, it is impossible to determine 
the threshold score for each domain which recog­
nizes CPG as “beneficial” or “not beneficial”.
To illustrate process described above we pres­
ent the use of AGREE instrument for the ap­
praisal of document dealing with postprandi­
al glycemic control issued by IDF. Individual 
items of the AGREE instrument are discussed 
one by one with clarification of their significance 
and our assessment of the extent to which the IDF 
guidelines meet a given criterion.
scope and purpose
1 General purpose of CPG has been precise­
ly defined.
1.1 AGREE clarification: this deals with the po­
tential health impact of a guideline on society and 
populations of patients. The overall objective(s) 
of the guideline should be described in detail and 
the expected health benefits from the guideline 
should be specific to the clinical problem.
1.2 IDF guidelines: according to the developers 
of the analyzed guidelines, the purpose of this 
guideline is to present data from reports that 
describe the relationship between postmeal glu­
cose and the development of diabetic complica­
tions. Based on these data, recommendations for 
the appropriate management of postmeal glucose 
in type 1 and type 2 diabetes have been devel­
oped. The recommendations are intended to assist 
and the manufacturers of recommended drugs 
or devices. The need to establish standard cri­
teria for guideline assessment has been recog­
nized by an inter national group of physicians, re­
searchers and those employed in various health 
care sectors inter ested in methodology CPG de­
velopment. The AGREE (Appraisal of Guidelines 
Research and Evaluation) instrument is the result 
of their cooperation.8 This instrument is a ques­
tionnaire, which, according to its authors, allows 
reproducible quality assessment of CPG.
The main objective of this paper is to review 
the rules of assessment and development of guide­
lines designed to influence clinical practice. It is 
neither a systematic nor comprehensive review, 
but more an attempt to introduce the AGREE 
instrument to readers and demonstration of its 
practical use for assessment of the recently pub­
lished document concerning postmeal hypergly­
cemia issued by the International Diabetes Fed­
eration (IDF) and available on the IDF website, 
recently also in Polish (www.idf.org). Its Polish 
version has also been published in the monthly 
Medycyna Praktyczna.9 The International Diabe­
tes Federation encompasses over two hundred 
other associations and organizations involved 
in diabetes therapy, rates among the most repu­
table and respected diabetic organizations, and 
its objective is education, prevention and treat­
ment of diabetes in the world.
AGrEE instrument The objective of the AGREE 
instrument is to establish a system for critical 
appraisal of guidelines.8 In this framework clin­
ical practice guidelines are systematically devel­
oped statements with aim to assist practitioners 
and patients in deciding appropriate management 
in specific clinical circumstances.10 Their purpose 
is to make explicit recommendations with a defi­
nite intent to influence what clinicians do.11
Quality of CPG is meant by the authors 
of the AGREE instrument as a degree of confi­
dence that: 1) appropriate steps have been tak­
en during the process of guideline development 
to avoid an error leading to formulation of un­
true recommendations, 2) the recommendations 
are applicable to patients, whose data have been 
used to establish the recommendations, and 
to similar (but potentially slightly different) pa­
tients, to whom the recommendations may apply 
in the future, and 3) there is a possibility of in­
troduction of a given recommendation to clinical 
practice. According to the AGREE, when assess­
ing the CPG quality, benefits, harms and costs re­
sulting from following individual recommenda­
tions and associated practical issues should be 
considered. Therefore, a critical look involves as­
sessment of methods, final wording of individu­
al recommendations and consideration of factors, 
which may influence introduction of the guide­
lines into practice.
The AGREE instrument may be used for assess­
ment of CPG dealing with any clinical situation. 
It may be used by health service managers, CPG 
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in the document). The Guideline Development 
Group included people with considerable expe­
rience in guideline development, healthcare de­
velopment and delivery, and people living with 
diabetes. Geographical representation included 
all IDF regions and countries in different states 
of economic development.
4.3 Our assessment: 3 (agree, no details).
5 The patients’ views and preferences have been 
sought.
5.1 AGREE clarification: information about pa­
tients’ experiences and expectations of health 
care should inform the development of clinical 
guidelines.
5.2 IDF guidelines: the developers mentioned 
as follows: “The process involved a broadly 
based group of people, including people with 
diabetes (…).”
5.3 Our assessment: 3 (agree, no details)
6 The target users of the guideline are clear­
ly defined.
6.1 AGREE clarification: the target users should 
be clearly defined in the guideline, so they can 
immediately determine if the guideline is rele­
vant to them.
6.2 IDF guidelines: “The recommendations are 
intended to assist clinicians and organizations 
in developing strategies to effectively manage 
postmeal glucose in people with type 1 and type 
2 diabetes, taking into consideration locally avail­
able therapies and resources. (…) Logic and clini­
cal judgment remain critical components of dia­
betes care and implementation of the guideline 
recommendations.”
6.3 Our assessment: 3 (agree, no details).
7 The guideline has been piloted among tar­
get users.
7.1 AGREE clarification: a guideline should have 
been pre­tested for further validation amongst 
its intended end users prior to publication. This 
process should be documented.
7.2 IDF guidelines: no data available.
7.3 Our assessment: 2 (disagree, no data 
available).
rigor of development
8 Systematic methods were sued to search for 
evidence.
8.1 AGREE clarification: “Details of the strate­
gy used to search for evidence should be provid­
ed including search terms used, sources consult­
ed and dates of the literature covered. Sources 
may include electronic databases (e.g. MEDLINE, 
EMBASE, CINAHL), databases of systematic re­
views (e.g. the Cochrane Library, DARE), jour­
nals, conference proceedings and other guidelines 
(e.g. the US National Guideline Clearinghouse, 
the German Guidelines Clearinghouse).”
8.2 IDF guidelines: “The evidence used in devel­
oping this guideline included reports from key 
meta­analyses, evidence­based reviews, clinical 
trials, cohort studies, epidemio logical studies, 
animal and basic science studies, position state­
ments and guidelines (English language only). 
clinicians and organizations in developing strate­
gies to effectively manage postmeal glucose in pa­
tients with type 1 and type 2 diabetes, taking into 
consideration locally available therapies and re­
sources. Postmeal glycemic control in pregnancy 
has not been addressed in this guideline.
1.3 Our assessment: 4 points (strongly agree).
2 The clinical question(s) covered by the guide­
line is(are) specifically described
2.1 AGREE clarification: a detailed description 
of the clinical questions covered by the guideline 
should be provided, particularly for the key rec­
ommendations (see item 17).
2.2 IDF guidelines: “As a basis for developing 
the recommendations, the Guideline Develop­
ment Group addressed four questions relevant 
to the role and importance of postmeal hyperg­
lycemia in diabetes management. The evidence 
supporting the recommendations is shown as ev­
idence statements (with the level of evidence in­
dicated at the end of the statement).” Those ques­
tions were as follows: 1) Is postmeal hyperglyce­
mia harmful? 2) Is treatment of postmeal hyper­
glycemia beneficial? 3) Which therapies are effec­
tive in controlling postmeal plasma glucose? 4) 
What are targets for postmeal glycemic control 
and how should they be assessed?
2.3 Our assessment: 4 points (strongly agree).
3 The patients to whom the guideline is meant 
to apply are specifically described.
3.1 AGREE clarification: there should be a clear 
description of the target population to be covered 
by a guideline. The age range, sex, clinical descrip­
tion, comorbidity may be provided.
3.2 IDF guidelines, according to their devel­
opers, should deal with postmeal glycemia both 
in type 1 and type 2 diabetic patients, but do not 
apply in pregnancy.
3.3 Our assessment: 3 (agree).
stakeholder involvement
4 The guideline development group includes 
individuals from all the relevant professional 
groups.
4.1 AGREE clarification: this item refers 
to the professionals who were involved at some 
stage of the development process. This may in­
clude members of the steering group, the research 
team involved in selecting and reviewing/rating 
the evidence and individuals involved in formu­
lating the final recommendations. This item ex­
cludes individuals who have externally reviewed 
the guideline (see item 13). Information about 
the composition, discipline and relevant exper­
tise of the guideline development group should 
be provided.
4.2 IDF guidelines: “The process involved 
a broadly based group of people, including pa­
tients with diabetes, healthcare professionals 
from diverse disciplines and people from non­
governmental organizations. The project was 
overseen by the Steering Committee (…) and 
input was provided by the entire Guideline De­
velopment Group (individual persons specified 
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the recommendations. A recommendation was 
made according to the level of scientific substan­
tiation based on evidence ratings whenever pos­
sible. However, when there was a lack of support­
ing studies, the Steering Committee formulated 
a consensus recommendation.”
10.3 Our assessment: 3 (agree)
11 The health benefits, side effects and risks 
have been considered in formulating the recom­
men dations.
11.1 AGREE clarification: the guideline should 
consider health benefits, side effects, and risks 
of the recommendations. These may include: sur­
vival, quality of life, adverse effects, and symptom 
management or a discussion comparing one treat­
ment option to another. There should be evidence 
that these issues have been addressed.
11.2 IDF guidelines: each recommendation 
was accompanied by an extensive description 
of evidence and a set of evidence­based state­
ments which constituted the the basis for 
the recommendations.
11.3 Our assessment: 3 (agree, however, no dis­
cussion on costs and non­monetary expenses in­
curred by a patient).
12 There is an explicit link between the recom­
mendations and the supporting evidence.
12.1 AGREE clarification: there should be an ex­
plicit link between the recommendations and 
the evidence on which they are based. Each rec­
ommendation should be linked with a list of ref­
erences on which it is based.
12.2 IDF guidelines: a link between the recom­
mendations and the evidence, on which they were 
based, was clearly identified in the text.
12.3 Our assessment: 3 (agree formally, recom­
mendation for treatment not resulting directly 
from the presented evidence).
13 The guideline has been externally reviewed 
by experts prior to its publication.
13.1 AGREE clarification: a guideline should be 
reviewed externally before it is published. Review­
ers should not have been involved in the devel­
opment group and should include some experts 
in the clinical area and some methodo logical ex­
perts. Patients’ representatives may also be in­
cluded. A description of the methodology used 
to conduct the external review should be pre­
sented, which may include a list of the review­
ers and their affi liation.
13.2 IDF guidelines: “The evidence cited to sup­
port the recommendations was reviewed by two 
independent external reviewers who were not 
part of the Guideline Development Committee. 
Comments from the external reviewers were then 
reviewed by the Steering Committee.” “The draft 
guideline was sent out for a wider external review 
to IDF member associations, global and regional 
IDF elected representatives, inter ested profession­
als, industry and others on IDF contact lists, for 
a total of 322 invitations. Thirty­eight comments 
from 20 external reviewers from five of the seven 
IDF regions (Africa, South East Asia, Western Pa­
cific, North America, Europe) were received. These 
A scientific writer with knowledge of diabetes ob­
tained relevant reports through a computerized 
search of available data using the PubMed and 
other search engines; scanning incoming jour­
nals in the medical library and reviewing the ref­
erences in pertinent s, major textbooks and syl­
labi from national and inter national meetings 
on the subjects of diabetes, using relevant title 
and text words (e.g. postprandial, postmeal, hy­
perglycemia, mealtime, self­monitoring, oxida­
tive stress, inflammation) as search criteria. Ev­
idence relating to both postmeal and postchal­
lenge plasma glucose was reviewed and cited as 
appropriate. A review of recent guidelines, posi­
tion statements and recent articles not identified 
in the universal search was also conducted to ob­
tain additional information that was potentially 
applicable to the questions. An electronic data­
base was created to include full reference informa­
tion for each report; abstracts for most of the re­
ports were included in the database. Members 
of the Steering Committee were asked to iden­
tify any additional reports or publications rel­
evant to the questions. In total, 1,659 reports 
were identified.”
8.3 Our assessment: 4 (strongly agree).
9 The criteria for selecting the evidence are 
clearly described.
9.1 AGREE clarification: criteria for including/
excluding evidence identified by the search should 
be provided. These criteria should be explicitly de­
scribed and reasons for including and excluding 
evidence should be clearly stated. For example, 
guideline authors may decide to only include ev­
idence from randomised clinical trials and to ex­
clude articles not written in English.
9.2 IDF guidelines: the authors used all avail­
able evidence and based their recommendations 
on those with highest quality. For this purpose 
they used the evidence­grading criteria system 
developed by the Scottish Intercollegiate Guide­
lines Network (SIGN, see tAbLE; for more infor­
mation on methods see the document on: www.
idf.org).
Note: the evidence­grading criteria system 
mentioned above gives the highest ranks to ran­
domized controlled trials, which pertain main­
ly to therapeutical questions and lower to prog­
nosis trials, which were the basis for the answer 
to question number 1.
9.3 Our assessment: 4 (strongly agree).
10 The methods used for formulating the rec­
ommendations are clearly described.
10.1 AGREE clarification: there should be a de­
scription of the methods used to formulate 
the recommendations and how final decisions 
were arrived at. Methods include, among others, 
a voting system, formal consensus techniques 
(e.g. Delphi, Glaser techniques). Areas of disagree­
ment and methods of resolving them should be 
specified.
10.2 IDF guidelines: “The Guideline Develop­
ment Committee met to discuss the evidence 
statements and supporting data and to develop 
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recommendations 4 Two­hour postmeal plasma 
glucose should not exceed 7.8 mmol/l (140 mg/dl) 
as long as hypoglycemia is avoided.
Self­monitoring of blood glucose should be con­
sidered because it is currently the most practical 
method for monitoring postmeal glycemia.
Efficacy of treatment regimens should be mon­
itored as frequently as needed to guide thera­
py towards achieving the postmeal plasma glu­
cose target.
15.3 Our assessment: 2 (disagree; see Addition­
al comments).
16 The different options for management 
of the condition are clearly presented.
16.1 AGREE clarification: a guideline should con­
sider the different possible options for screening, 
prevention, diagnosis or treatment of the condi­
tion it covers.
16.2 IDF guidelines: as stated above, a num­
ber of treatment options described by the au­
thors cover almost every hyperglycemia control 
method.
16.3 Our assessment: 4 (agree).
17 Key recommendations are easily 
identifiable.
17.1 AGREE clarification: users should be able 
to find the most relevant recommendations easily. 
These recommendations answer the main clinical 
questions that have been covered by the guideline. 
They can be identified in different ways. For ex­
ample, they can be summarised in a box, typed 
in bold, underlined or presented as flow charts 
or algorithms.
17.2 IDF guidelines: the above mentioned sug­
gestions have been fulfilled.
17.3 Our assessment: 4 (agree).
18 The guideline is supported with tools for 
application.
18.1 For a guideline to be effective it needs 
to be disseminated and implemented with addi­
tional materials. These may include for example, 
a summary document, a quick reference guide, 
educational tools, leaflets for patients, comput­
er support.
18.2 IDF guidelines: no materials mentioned 
above.
18.3 Our assessment: 2 (disagree; see Addition­
al comments).
comments were reviewed by the Steering Com­
mittee and considered in developing the final 
document.”
13.3 Our assessment: 4 (agree).
14 A procedure for updating the guideline is 
provided.
14.1 AGREE clarification: guidelines need to re­
flect current research. There should be a clear 
statement about the procedure for updating 
the guideline. For example, a timescale has been 
given, or a standing panel receives regularly up­
dated literature searches and makes changes as 
required.
14.2 IDF guidelines: IDF considers review and 
update within three years.
14.3 Our assessment: 3 (agree, although the up­
date intent is not precise).
clarity and presentation
15 The recommendations are specific and 
unambiguous.
15.1 AGREE clarification: a recommendation 
should provide a concrete and precise description 
of which management is appropriate in which sit­
uation and in what patient group, as permitted 
by the body of evidence. However, evidence is not 
always clear cut and there may be uncertainty 
about the best management. In this case the un­
certainty should be stated in the guideline.
15.2 IDF guidelines: below we present recom­
mendations corresponding to the four main 
questions:
Question 1 Is postmeal hyperglycemia harmful?
recommendation 1 Postmeal hyperglycemia is 
harmful and should be addressed.
Question 2 Is treatment of postmeal hypergly­
cemia beneficial?
recommendation 2 Implement treatment strate­
gies to lower postmeal plasma glucose in patients 
with postmeal hyperglycemia.
Question 3 Which therapies are effective in con­
trolling postmeal plasma glucose?
recommendation 3 A variety of both non­
­pharmaco logic and pharmaco logic therapies 
should be considered to target postmeal plas­
ma glucose.
Question 4 What are targets for postmeal glyce­
mic control and how should they be assessed?
tAbLE Evidence‑grading criteria according to Scottish Intercollegiate Guidelines Network
1 +  + High‑quality meta‑analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1 + Well‑conducted meta‑analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1 – Meta‑analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2 +  + High‑quality systematic reviews of case‑control or cohort studies; 
high‑quality case control or cohort studies with a very low risk of confounding bias and a high probability that the relationship is causal
2 + Well‑conducted case‑control or cohort studies with a low risk of confounding bias or chance and a moderate probability that 
the relationship is causal; well‑conducted basic science with a low risk of bias
2 – Case‑control or cohort studies with a high risk of confounding bias or chance and a significant risk that the relationship is not causal
3 Non‑analytic studies (for example s, case series)
4 Expert opinion
Abbreviations: RCT – randomized controlled trials
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Amylin Pharmaceuticals, Eli Lilly and Company, 
LifeScan, Inc., Merck & Co. Inc, Novo Nordisk A/S, 
Roche Diagnostics GmbH, Roche Pharmaceuti­
cals. These companies did not take part in the de­
velopment of the guideline. However, these and 
other commercial organizations on IDF’s commu­
nications list were invited to provide comments 
on draft versions of the guideline.”
22.3 Our assessment: 3 (agree, although the lev­
el of authors’ independence from the industry is 
usually much more complex than “no external 
funding” recommended by the AGREE).
23 Conflict of inter est of guideline development 
members have been recorded.
23.1 AGREE clarification: there are circumstanc­
es when members of the development group may 
have conflicts of inter est. For example, this would 
apply to a member of the development group 
whose research on the topic covered by the guide­
line is also funded by a pharmaceutical compa­
ny. There should be an explicit statement that all 
group members have declared whether they have 
any conflict of inter est.
23.2 IDF guidelines: members of the Guideline 
Development Committee have declared relevant 
dualities of inter est in the topic and in relation­
ships with commercial enterprises, governments 
and non­governmental organizations. No fees 
were paid to the Guideline Development Com­
mittee members in connection with the current 
activity.
23.3 Our assessment: 3 (agree to a degree sim­
ilar to other guidelines and documents, proba­
bly in the future the authors would be required 
much more detailed declaration).
Final comments Analysis of IDF guidelines using 
the AGREE instrument allowed us to make certain 
observations concerning both documents.
First, the examination of the utility of the AGREE 
instrument suggests that it should not be used 
to specifically determine clinical usefulness of CPG 
or to make unambiguous decisions about adher­
ing to their recommendations. Instead, AGREE 
should rather be used to identify the domains, 
which should be more closely considered by both 
the CPG users and the persons responsible for 
their update. Numerical scores attributed to in­
dividual domains will lack significance with­
out reference to clinical context, which requires 
thorough expertise. Clinical context is an essen­
tial component of the process of CPG develop­
ment and assessment. Clinical questions them­
selves, which should be answered by individu­
al recommendations, are of fundamental signif­
icance. In the case of the IDF guidelines consid­
ered here, clinical questions concern postmeal 
blood glucose; it could, however, be noted that al­
though the evidence of harm of postmeal hyper­
glycemia is not in doubt, it has not been demon­
strated by authors of IDF guidelines that treat­
ment aiming at its reduction was associated with 
a decrease in mortality caused by diabetic compli­
cations. This observation follows the fact that it 
Applicability
19 The potential organizational barriers in apply­
ing the recommendations have been discussed.
19.1 AGREE clarification: applying the recom­
mendations may require changes in the current 
organisation of care within a service or a clin­
ic which may be a barrier to using them in dai­
ly practice. Organisational changes that may be 
needed in order to apply the recommendations 
should be discussed.
19.2 IDF guidelines: taking into account the low 
level of precision and explicitness of recom­
mendations, the above aspects have not been 
considered.
19.3 Our assessment: 2 (disagree, not applicable).
20 The potential cost implication of applying 
recommendations have been considered.
20.1 AGREE clarification: the recommendations 
may require additional resources in order to be 
applied. For example, there may be a need for 
more specialised staff, new equipment, expen­
sive drug treatment. These may have cost impli­
cations for health care budgets. There should be 
a discussion of the potential impact on resourc­
es in the guideline.
20.2 IDF guidelines: the cost issue has been 
treated superficially: “Although cost will remain 
an important factor in determining appropriate 
treatments, controlling glycemia is ultimately 
much less expensive than treating the complica­
tions of diabetes.”
20.3 Our assessment: 2 (disagree).
21 The guideline presents key review criteria for 
monitoring and/or audit purposes.
21.1 AGREE clarification: measuring the ad­
herence to a guideline can enhance its use. This 
requires clearly defined review criteria that 
are derived from the key recommendations 
in the guideline.
21.2 IDF guidelines: treatment goals are clear­
ly specified: HbA1c <6.5%, premeal (fasting) plas­
ma glucose <5.5 mg/dl, 2­hour postmeal plasma 
glucose <7.8 mg/dl.
21.3 Our assessment: 3 (agree, although prac­
tical aspects of reaching those goals remain 
uninvestigated).
Editorial independence
22 The guideline is ly independent from the 
funding body.
22.1 AGREE clarification: some guidelines are 
developed with external funding (e.g. Govern­
ment funding, charity organisations, pharma­
ceutical companies). Support may be in the form 
of financial contribution for the whole develop­
ment, or for parts of it, e.g. printing of the guide­
lines. There should be an explicit statement that 
the views or inter ests of the funding body have 
not influenced the final recommendations. Please 
note: If it is stated that a guideline was developed 
without external funding, then you should an­
swer “strongly agree”.
22.2 IDF guidelines: “This activity was support­
ed by unrestricted educational grants from:
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is quite difficult to separate therapeutical effect 
associated with treatment of fasting and post­
meal hyperglycemia. It should be remembered 
that maintenance of optimum glycemic control, 
i.e. both fasting and postmeal, assessed also in­
directly using HbA1c value, remains the main goal 
of diabetes treatment. The IDF guidelines are 
a document of a world­wide application, i.e. ad­
dressed to a number of various health care sys­
tems, emphasizing the significance of postmeal 
hyperglycemia treatment that should be consid­
ered in management of all diabetic patients.
The third and, in our opinion, the most im­
portant observation concerns the understand­
ing of the CPG’s role. We believe that it should 
be a set of recommendations, which assists phy­
sicians and other health care providers in mak­
ing optimal decisions in patient care. The objec­
tive of their development is therefore a direct 
impact on actions of physicians, health care pro­
viders and patients. On the other hand the IDF 
document is mostly a position statement, i.e. 
a set of statements, saying that (postmeal) hy­
perglycemia is harmful, that (postmeal) hyper­
glycemia should be treated using usual meth­
ods, and that self­measurement of blood glucose 
by patients is useful. Irrespective of a general na­
ture of such statements (and not recommenda­
tions), the least specific part pertains to treatment 
of (postmeal) hyperglycemia, where the authors 
of the IDF document say as follows: “A variety 
of both non­pharmaco logic and pharmaco logic 
therapies should be considered to target postmeal 
plasma glucose.” From the user’s (physician, nurse 
or patient) point of view, precise information 
concerning selection of particular medications 
would be more desirable. Lack of precise recom­
mendations for treatment of (postmeal) hyperg­
lycemia is a result of inadequate evidence, which 
would allow the authors of “guidelines” to deter­
mine relative benefits of following various acces­
sible treatment methods and to suggest practi­
cal instructions.
In summary one should consider the follow­
ing question: “Would you recommend application 
of those guidelines in practice?” The AGREE in­
strument allows the following options: “strong­
ly recommend”, “recommend (with reservations 
or after amendments)”, “not recommend” and 
“not certain”. In our opinion,the IDF “guidelines” 
concerning postmeal glucose control may be used 
to emphasize the role of hyperglycemia control, 
including postmeal hyperglycemia, in diabetes 
treatment. Unfortunately, they are not helpful 
when selecting the optimal treatment method, 
probably since the associated clinical trial evi­
dence is still limited. It seems that physicians 
and patients, who would like to receive detailed 
instructions concerning management of post­
meal hyperglycemia, have to wait for the follow­
ing update of the document.
